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Background: Among schizophrenia patients relapsed on an oral antipsychotic (AP), this study compared the
impact of switching to atypical AP long-acting injectable therapy (LAT) versus continuing oral APs on hospitalization
and emergency room (ER) visit recurrence.
Methods: Electronic records from the Premier Hospital Database (2006-2010) were analyzed. Adult patients receiving
oral APs during a schizophrenia-related hospitalization were identified and, upon relapse (i.e., rehospitalization for
schizophrenia), were stratified into (a) patients switching to atypical LAT and (b) patients continuing with oral APs.
Atypical LAT relapse patients were matched 1:3 with oral AP relapse patients, using a propensity score model.
Andersen-Gill Cox proportional hazards models assessed the impact of atypical LAT versus oral AP on time to multiple
recurrences of all-cause hospitalizations and ER visits. No adjustment was made for multiplicity.
Results: Atypical LAT (N = 1032) and oral AP (N = 2796) patients were matched and well-balanced with respect to
demographic (mean age: 42.1 vs 42.4 years, p = .5622; gender: 43.6% vs 44.6% female, p = .5345), clinical, and hospital
characteristics. Over a mean 30-month follow-up period, atypical LATs were associated with significantly lower mean
number of rehospitalizations (1.25 vs 1.61, p < .0001) and ER visits (2.33 vs 2.67, p = .0158) compared with oral APs, as
well as fewer days in hospital (mean days: 13.46 vs. 15.69, p = .0081). Rehospitalization (HR 0.81, 95% CI 0.76–0.87,
p < .0001) and ER visit (HR 0.88, 95% CI 0.87–0.93, p < .0001) rates were significantly lower for patients receiving
atypical LAT versus oral APs.
Conclusions: This hospital database analysis found that in relapsed schizophrenia patients, atypical LATs were
associated with lower rehospitalization and ER visit rates than oral APs.
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Schizophrenia usually appears in early adulthood, and
approximately two-thirds of individuals with this disease
have persisting or fluctuating symptoms even with opti-
mal treatment [1,2]. Inpatient care represents the pri-
mary driver of costs associated with schizophrenia,
accounting for between one-third and two-thirds of the
total direct health care costs of patients with schizophre-
nia [3-6]. Indeed, most of these patients will experience
a chronic course with many relapses, characterized by
an exacerbation of psychosis, emergency room (ER) visits,
and rehospitalizations [7-9]. These relapse events are often
associated with significant changes in the treatment of
schizophrenia and initiation of new therapies [10,11].
The primary goal of pharmacotherapy with antipsy-
chotics (APs) in patients with schizophrenia is to pre-
vent relapse and to reduce the severity of subsequent
acute episodes over time [12,13]. Compared with typical
APs, atypical APs are generally considered to be associ-
ated with a lower risk of serious adverse events and are
therefore the first-line therapeutic agents of choice for
patients with schizophrenia in most countries [14-16]. In
practice, the effectiveness of oral AP treatment is often
undermined by poor adherence [17], which is associated
with an increased frequency of relapse and hospitalization
rates, more severe symptoms, longer inpatient stays, and
higher hospital costs [18-21].
It has been shown that AP long-acting injectable ther-
apy (LAT) can significantly improve adherence, reduce
symptoms, and reduce the risk of relapse and rehospi-
talization, particularly for severely ill patients [9,22,23].
There are currently three atypical APs available in long-
acting forms: risperidone (RISPERDAL® CONSTA®),
paliperidone palmitate (INVEGA® SUSTENNA®), and
olanzapine (ZYPREXA® RELPREVV®) [24-26]. Risperi-
done is indicated for the treatment of schizophrenia as
one injection every 2 weeks, whereas paliperidone palmi-
tate is a once-a-month agent approved for the acute and
maintenance treatment of schizophrenia in adults [24,25].
Olanzapine is approved for the treatment of schizophrenia
as one injection every 2 to 4 weeks but is available only
through a restricted distribution program [26]. Because
there is to date limited use of olanzapine LAT in clinical
practice and given its markedly different profile from the
two other atypical AP LATs, this analysis focused on ris-
peridone and paliperidone palmitate LATs.
Most previous studies have found a beneficial effect of
atypical LATs in terms of rehospitalizations using a pre-
post study design, where each patient acted as his or her
own control [9,20,22,27-37]. In addition, previous stud-
ies mostly focused on the rate of rehospitalization, not
taking into account that hospitalizations and ER visits
may be recurrent events in this population. This study
used a matched-cohort design to compare the effect ofswitching from oral APs to atypical LATs (risperidone or
paliperidone palmitate) with that of continuing to take
oral APs on the recurrence of hospitalizations and ER
visits among patients with schizophrenia who relapsed.
Methods
Data source
Health Insurance Portability and Accountability Act fully
compliant, deidentified records were retrieved retro-
spectively from the Premier Perspective Comparative
Hospital Database (Premier), the largest hospital-based
database in the United States, covering from the first
quarter of 2006 to the fourth quarter of 2010. This data-
base provides detailed information for more than 45 mil-
lion inpatient discharges and 310 million hospital
outpatient visits from more than 600 acute care hospi-
tals across all US regions. Data elements included demo-
graphics (e.g., age, gender, marital status, race, payer
type), visit-level information (e.g., primary and secondary
diagnoses), hospital characteristics (e.g., urban, teaching,
number of beds, region), and detailed drug use informa-
tion (e.g., drug name, dosage strength, dispensed quan-
tity). As opposed to centralized health care claims
recorded by insurance companies, patients’ medical in-
formation available in the Premier database comes from
records collected for billing purposes at the hospital
level. Institutional review board (IRB) and informed con-
sent were not required for this study.
Study design
A retrospective cohort design was used to identify pa-
tients with schizophrenia treated with APs who relapsed.
More specifically, the study included adult patients (aged
at least 18 years) receiving oral APs during a first
schizophrenia-related hospitalization (defined as hospi-
talizations with (i) a primary or admitting diagnosis of
schizophrenia according to International Classification
of Diseases, 9th Revision, Clinical Modification [ICD-9-
CM]: 295.xx; (ii) a primary or admitting diagnosis of
other mental disorders [ICD-9-CM diagnosis: 290.xx-
294.xx, 296.xx-319.xx] and an accompanying diagnosis
of schizophrenia, or (iii) a primary or admitting diagno-
sis of injury and poisoning [ICD-9-CM diagnosis: 800.
xx-999.xx] and an accompanying diagnosis of schizo-
phrenia). Patients were further stratified upon the next
schizophrenia rehospitalization (i.e., schizophrenia re-
lapse) into the following mutually exclusive exposure
groups: (a) patients switching to paliperidone palmitate
or risperidone injectable (“atypical LAT group”) and (b)
patients continuing with oral APs (“oral AP group”). The
index hospitalization (i.e., schizophrenia relapse) had
to occur at least 3 months before the data cutoff date
(December 2010). Figure 1 depicts the study design
scheme for this population.
Oral cohort
First schizophrenia-related
hospitalization with >1 dispensing
of oral AP and no LAT
Index hospitalization (i.e., relapse):




hospitalization with >1 dispensing
of oral AP and no LAT
Index hospitalization (i.e., relapse):
Patients switching to atypical LAT upon their
next schizophrenia-related re-hospitalization
January 1, 2006
Observation period for assessment of
ER and re-hospitalizations
December 31, 2010
Figure 1 Study design. AP, antipsychotic; ER, emergency room; LAT, long-acting therapy.
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End points for this study were the number of rehospi-
talizations and the number of ER visits occurring after
the index hospitalization, which are avoidable events
representing relapses not managed through outpatient
services. Number of days in hospital over the entire ob-
servation period was reported. ER visits resulting in hos-
pitalizations counted as one event for the latter end
point. Additionally, the time to first rehospitalization (or
ER visit) was defined as the number of months between
the index hospitalization and the first rehospitalization
(or ER visit) during follow-up. Finally, the frequency of
events within the same month or within 1, 3, and
6 months after the index hospitalization was also
reported. As depicted in Figure 1, these study end points
were evaluated from the index hospitalization (i.e., re-
lapse) to the data cutoff date (December 31, 2010). In
addition, results were generated separately for all-cause
visits, mental disorder–related visits (at least one diagnosis
for mental disorders [ICD-9-CM diagnosis: 290.xx-319.
xx]), and schizophrenia-related visits (at least one diagno-
sis for schizophrenia [ICD-9-CM diagnosis: 295.xx]).
Matching algorithm
To minimize the potential of confounding factors, each
patient in the atypical LAT group was matched with up
to three unique patients in the oral AP group based on
both propensity scores, using the 2.5 percentiles of the
propensity score distribution and exact matching factors.
These criteria were chosen to achieve both clinical and
statistical balance between cohorts without losing a sig-
nificant proportion of the atypical LAT group. Propen-
sity scores were calculated using a multivariate logistic
regression model in which being in the atypical LAT
group was the dependent variable and characteristicsavailable at the first hospitalization (type of oral AP
used) and at the index hospitalization (sociodemographic
characteristics, hospital characteristics, and clinical char-
acteristics [e.g., admitting and primary diagnoses, admit-
ting and attending physician specialty, length of ER stay,
degree of severity, number of distinct AP agents used,
type of oral AP agents received during the first
hospitalization, suicidal behavior, surgery, discharge sta-
tus, year of admission, time between first hospitalization
and index hospitalization, and time between index
hospitalization and data cutoff date]) were used as predic-
tors of being in the atypical LAT group. Exact matching
factors included schizophrenia as the primary diagnosis,
categories of index hospitalization length of stay, psych-
iatry admitting physician specialty, and the number of AP
agents used during the index hospitalization.
Statistical analysis
Descriptive statistics were generated to summarize base-
line characteristics and study end points. Frequency
counts and percentages were used to summarize cat-
egorical variables while means and standard deviations
were used for continuous variables. To adjust for the
non-independence of the matched cohorts, statistical dif-
ferences between cohorts were assessed using McNemar
tests for categorical variables and the paired two-
sided t tests for continuous variables.
Since a patient might experience multiple recurrences
of hospitalizations and of ER visits, the Andersen-Gill
extension of the Cox proportional hazard model was
used to assess the impact of atypical LAT versus oral AP
on the time to recurrences of these events [38]. In this
extension, a subject contributes to the risk set for an
event as long as the patient is under observation at the
time the event occurs. Along with the hazard ratio, 95%
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lysis was conducted for all-cause visits and for the subset
of mental disorder-related visits (at least one diagnosis
of mental disorders [ICD-9-CM code: 290-319]) and of
schizophrenia-related visits (at least one diagnosis for
schizophrenia [ICD-9-CM diagnosis: 295.xx]). A two-
sided alpha error of 0.05 was used to declare statistical
significance. No adjustment was made for multiplicity.
All statistical analyses were conducted using SAS® Version
9.2 (SAS Institute, Inc., Cary, NC, USA).
Results
Baseline characteristics
Among the 122,129 patients receiving oral APs in their
first AP hospitalization, 1092 patients switched to an
atypical LAT during a second schizophrenia-related
hospitalization (whereas 35,841 patients continued to
take oral APs). Among these patients, a total of 1032
atypical LAT patients (94.5% of all patients) were
matched with 2796 oral AP patients. The baseline demo-
graphics and clinical characteristics of the matched pop-
ulations at the index hospitalization are shown in
Table 1. Atypical LAT and oral AP groups appeared well
balanced with respect to mean age (42.1 vs 42.4 years,
p = .5622), gender (43.6% vs 44.6% female, p = .5345),
race, region, payer type, hospital characteristics, admit-
ting diagnosis, admitting physician specialty, and degree
of illness severity (p > .05 for all). The mean length of
stay (16.3 vs 16.0 days, p = .6142), the mean time be-
tween first hospitalization and the index hospitalization
(8.0 vs 7.5 months, p = .1186), and the mean time be-
tween index hospitalization and data cutoff date (29.8 vs
30.3 months, p = .2953) appeared to be not statistically
significantly different between atypical LAT and oral AP
groups.
Rehospitalizations and emergency room visits
Table 2 presents descriptive statistics on rehospitaliza-
tion rates and ER visits after the index hospitalization.
Over a mean 30-month follow-up period, atypical LAT
patients were associated with a significantly lower mean
number of all-cause rehospitalizations (1.25 vs 1.61,
p < .0001), mental disorder-related rehospitalizations
(1.24 vs 1.59, p < .0001), schizophrenia-related rehospi-
talizations (1.15 vs 1.41, p = .0005), and all-cause ER visits
(2.33 vs 2.67, p = .0158) compared with oral AP patients.
The frequency of all-cause rehospitalizations within the
same month (0.07 vs 0.09, p = .0688), within 1 month
(0.15 vs 0.20, p = .0286), within 3 months (0.30 vs 0.38,
p = .0288), and within 6 months (0.48 vs 0.58, p = .0029)
was consistently lower for the atypical LAT group than
for the oral AP group. Similarly, frequencies for mental
disorder-related rehospitalizations were significantly
lower for the atypical LAT group than for the oral AP(same month: 0.07 vs 0.09, p = .0786; 1 month: 0.15 vs
0.20, p = .0360; 3 months: 0.30 vs 0.37, p = .0333; and
6 months: 0.48 vs 0.58, p = .0032). All-cause and mental
disorder-related mean days in hospital were also smaller
for the atypical LAT cohort (all-cause: 13.46 vs. 15.69,
p = .0081; mental disorder-related: 13.44 vs. 15.62, p = .0093,
schizophrenia-related: 12.79 vs. 14.28, p = .0893).Recurrence of events
Figure 2 presents the results of the Cox proportional haz-
ards model with recurrent events using the Andersen-Gill
extension. The risk of all-cause rehospitalizations was sig-
nificantly lower for the atypical LAT group than for the
oral AP group (hazard ratio [HR] 0.81, 95% confidence
interval [CI] 0.76–0.87, p < .0001). Consistently significant
results were found for all-cause ER visits (HR 0.88, 95% CI
0.87–0.93, p < .0001).
Similarly, significantly lower risks for mental disorder-
related events were observed for atypical LAT patients
relative to oral AP patients (rehospitalizations: HR 0.85,
95% CI 0.80–0.91, p < .0001; ER visits: HR 0.94, 95% CI
0.88–0.99, p = .0285). A lower risk of schizophrenia-
related rehospitalizations was found for the atypical LAT
group (HR: 0.88, 95% CI 0.82-0.95, p = .0007), whereas no
difference between cohorts was found for schizophrenia-
related emergency-room visits (HR: 0.99, 95% CI 0.92-
1.05, p = .6851).Discussion
This real-world retrospective study compared the recur-
rence of hospitalizations and ER visits between relapsed
patients with schizophrenia treated with atypical LATs
and those treated with oral AP agents. The results
showed a 19% to 12% significantly lower likelihood of
all-cause rehospitalizations and ER visits for the atypical
LAT group relative to the oral AP group. Results were
similar when restricting the analysis to the subset of
events associated with a diagnosis for mental disorders.
In the absence of direct clinical assessment data, this
study used rehospitalizations and ER visits as a proxy for
instances of relapses. This is warranted as hospitalizations
are related to a wide range of schizophrenic outcomes
such as suicidal attempt, violence, and medication side ef-
fects [9,27,39-41]. Schizophrenia disease is often charac-
terized by episodes of relapse alternating with periods of
complete or partial remission [8]. Successive relapses can
reduce the degree and duration of the following remission,
worsen disability, and increase refractoriness to future
treatment [8,42]. Relapses are associated with high medical
and non-medical costs as well as productivity loss [40].
Thus, rehospitalization, which is frequently the most ex-
pensive healthcare cost component for psychotic patients,
is a relevant relapse measure [40].
Table 1 Baseline demographics and clinical characteristics at index hospitalization
Variable Atypical LAT Oral AP p value1
(N = 1032) (N = 2796)
Age, mean ± SD [median] 42.1 ± 14.4 [42.5] 42.4 ± 13.7 [43.0] .5622
Female, n (%) 450 (43.6) 1246 (44.6) .5345
Marital status, n (%)
Single 869 (84.2) 2364 (84.5) .8531
Married 70 (6.8) 171 (6.1) .3501
Other 93 (9.0) 260 (9.3) .3217
Unknown 0 (0.0) 1 (0.0) -
Race, n (%)
White 483 (46.8) 1302 (46.6) .8515
Black 327 (31.7) 908 (32.5) .4751
Hispanic 29 (2.8) 77 (2.8) .7488
Other 193 (18.7) 509 (18.2) .6339
Primary payer type, n (%)
Medicare 509 (49.3) 1429 (51.1) .1455
Medicaid 327 (31.7) 864 (30.9) .3670
Commercial indemnity 39 (3.8) 96 (3.4) .6600
Self-pay 32 (3.1) 77 (2.8) .6265
Managed care 68 (6.6) 183 (6.5) .8717
Other 57 (5.5) 147 (5.3) .6385
Hospital characteristics, n (%)
Urban 920 (89.1) 2512 (89.8) .4343
Teaching 422 (40.9) 1195 (42.7) .1380
Large (≥500 beds) 311 (30.1) 875 (31.3) .2576
Region of the hospital, n (%)
South 438 (42.4) 1151 (41.2) .5484
Midwest 247 (23.9) 703 (25.1) .6391
West 187 (18.1) 491 (17.6) .3662
Northeast 160 (15.5) 451 (16.1) .2229
Admission source, n (%)
Physician referral 294 (28.5) 761 (27.2) .2282
ER 547 (53.0) 1530 (54.7) .2747
Clinic referral 18 (1.7) 63 (2.3) .1819
Court/law enforcement 26 (2.5) 56 (2.0) .2773
Transfer from hospital 80 (7.8) 210 (7.5) .7994
Other 67 (6.5) 176 (6.3) .9110
Admitting physician specialty, n (%)
Psychiatry 935 (90.6) 2579 (92.2) .3415
Internal medicine (internist/hospitalist) 13 (1.3) 34 (1.2) .8026
Family/General medicine 6 (0.6) 25 (0.9) .1495
Other 76 (7.4) 158 (5.7) .1448
Unknown 2 (0.2) 0 (0.0) -
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Table 1 Baseline demographics and clinical characteristics at index hospitalization (Continued)
Attending physician specialty, n (%)
Psychiatry 985 (95.4) 2702 (96.6) .0366
Internal medicine (internist/hospitalist) 12 (1.2) 32 (1.1) .9013
Family/General medicine 3 (0.3) 6 (0.2) .4054
Other 32 (3.1) 56 (2.0) .0258
Most frequent admitting diagnoses, n (%)
Schizophrenia3 627 (60.8) 1721 (61.6) .5098
Other mental disorders4 150 (14.5) 403 (14.4) .9093
Injury and poisoning7 4 (0.4) 5 (0.2) .0896
Other 21 (2.0) 61 (2.2) .9263
Unknown 230 (22.3) 606 (21.7) .5012
Most frequent primary diagnoses, n (%)
Schizophrenia3 976 (94.6) 2686 (96.1) .0897
Paranoid (ICD-9-CM: 295.3) 426 (43.6) 1165 (43.4) .7467
Schizoaffective disorder (ICD-9-CM: 295.4) 370 (37.9) 1047 (39.0) .4872
Unspecified (ICD-9-CM: 295.9) 80 (8.2) 209 (7.8) .8782
Residual (ICD-9-CM: 295.6) 62 (6.4) 162 (6.0) .4025
Other 38 (3.9) 103 (3.8) .6650
Other mental disorders4 46 (4.5) 90 (3.2) .2541
Diseases of the circulatory system5 0 (0.0) 1 (0.0) -
Injury and poisoning6 8 (0.8) 12 (0.4) .0455
Other 2 (0.2) 7 (0.3) .7815
Degree of severity, n (%)7
Minor 284 (27.5) 764 (27.3) .6578
Moderate 680 (65.9) 1847 (66.1) .9115
Major 60 (5.8) 160 (5.7) .7687
Extreme 8 (0.8) 25 (0.9) .3657
Number of distinct APs used, mean ± SD [median]2 2.2 ± 1.0 [2.0] 2.2 ± 1.0 [2.0] 1.0000
Suicidal behavior, n (%)8 115 (11.1) 303 (10.8) .6393
Surgery during index hospitalization, n (%) 21 (2.0) 76 (2.7) .0518
Discharge status, n (%)
Home 853 (79.4) 2425 (80.4) .1478
Transferred to hospice, rehabilitation center, or nursing home 64 (6.9) 230 (7.6) .3959
Discharged/transferred to psychiatric facility 46 (4.5) 153 (5.1) .0825
Other/Unknown 69 (6.7) 207 (6.9) .9592
Length of stay, days, mean ± SD [median] 16.3 ± 19.4 [11.0] 16.0 ± 22.3 [10.0] .6142
Time between first hospitalization and index hospitalization, months, mean ± SD [median] 8.0 ± 10.2 [3.0] 7.5 ± 9.8 [3.0] .1186
Time between index hospitalization and data cutoff date, months, mean ± SD [median] 29.8 ± 16.1 [29.0] 30.3 ± 16.1 [29.0] .2953
Year of admission, n (%)
2006 200 (19.4) 550 (19.7) .7883
2007 189 (18.3) 548 (19.6) .1657
2008 228 (22.1) 603 (21.6) .3887
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Table 1 Baseline demographics and clinical characteristics at index hospitalization (Continued)
2009 241 (23.4) 656 (23.5) .9749
2010 174 (16.9) 439 (15.7) .4453
AP, antipsychotics; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; LAT, long-acting therapy; SD, standard deviation.
Notes:
1. Calculated using McNemar tests for categorical variables and two-sided paired t tests for continuous variables.
2. Oral and injection forms of the same compound counted as one AP agent.
3. Defined as ICD-9-CM codes: 295.x.
4. Defined as ICD-9-CM codes: 290-294, 296-319.
5. Defined as ICD-9-CM codes: 390-459.
6. Defined as ICD-9-CM codes: 800-999.
7. Based on an algorithm developed by 3 M Health Information Systems (Salt Lake City, UT, USA). Constructed by considering (1) the primary admitting diagnosis,
(2) the secondary diagnoses, (3) the age of the patient, and (4) the presence of certain procedures.
8. Identified using ICD-9-CM diagnosis codes for suicidal tendencies, suicidal ideation, suicide and self-inflicted injury, injury undetermined whether accidentally or
purposely inflicted, and poisoning by drug, medicinal, and biological substances.
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lapsed population. Patients receiving atypical LAT in-
stead of oral AP may be more difficult to treat, with
poorer adherence to medication and/or with more se-
vere symptoms. In the absence of patients’ complete
medical history, imposing a previous hospitalization with
AP utilization prior to the index hospitalization served
as an exact matching criterion to identify similar groups
of patients. Along with the choice of the study design,
the matching algorithm used in the current study con-
tributed to diminishing the risk of selection bias
resulting from confounding factors between groups. A
comprehensive list of demographics and clinical charac-
teristics available during the index hospitalization was
included in the exact matching algorithm and propensity
scores model. Moreover, the sample sizes allowed the
authors to match each atypical LAT patient with up to
three oral AP patients, thus increasing the statistical
power of the analyses.
The descriptive results of this study showed that atyp-
ical LAT patients had a significantly lower rate of
rehospitalizations compared with oral AP patients in
addition to a non-significantly longer time period be-
tween the index hospitalization and the first rehospi-
talization (Table 2). These two factors were combined in
one statistical analysis, the Andersen-Gill extension of
the Cox regression model, to calculate the risk of time
to multiple recurrences of hospitalizations and ER visits.
The Andersen-Gill model uses a counting process ap-
proach which relates the intensity function of event re-
currences to the covariates multiplicatively where all
events contribute equally to the hazard function. The
hazard ratios of recurrent events calculated using this
method confirmed the descriptive results that patients
using atypical LATs have a lower risk of rehospitalizations
and ER visits compared with oral AP patients.
This study corroborates the findings from other stud-
ies that have found a beneficial effect of atypical LATs in
terms of rehospitalizations [9,20,22,27-37]. Some of
these studies used a pre-post study design, where eachpatient acted as his or her own control, and found that
LATs were associated with a decrease in hospitalizations
ranging from 34% to 89% [20,22,27-34]. The current
analysis based on a matched cohort design found that
LATs were associated with a 19% reduction in the risk of
recurrence of hospitalizations when compared to
matched oral AP patients. The slightly smaller effect
found in the current analysis may be explained in part
by the study design, where the comparison was made on
relapsed oral AP patients, which are likely an healthier
population than the subset of patients switching to LATs
(and hence are expected to have fewer rehospitalizations).
Focusing on the relapsed population (patients already ex-
periencing a second schizophrenia-related hospitalization)
and the matching approach have helped to address this
bias, but it is possible that unobservable characteristics
were still different between cohorts, therefore explaining
the smaller effect found here. However, the general
consistency of the results throughout different methods,
study designs, and study populations suggests that atypical
LATs may be more effective than oral APs in avoiding pa-
tient relapse. Moreover, it has been shown that inpatient
care can account for up to two-thirds of the total direct
healthcare costs for schizophrenia patients in the U.S.
[3,4,6]. Thus, the 19% decrease in the risk of recurrence of
rehospitalization found in the current study suggest that
the increased use of LATs compared to oral AP may be as-
sociated with substantial cost savings in relapsed patients
with schizophrenia. Further studies analyzing costs of hos-
pitalizations between patients using atypical LATs and
matched oral AP patients are warranted.
The present study has several limitations: (a) The data
were subject to billing inaccuracies and missing data. (b)
As the Premier network regroups only a subset of facil-
ities in the United States, the history of rehospi-
talizations and ER visits for a given patient may be
incomplete. Moreover, it was not possible in the Premier
database to link patient records across facilities, and,
therefore, to know whether or not the entire continuum
of care of patients was captured. (c) Patients were
Table 2 Frequency of rehospitalizations and emergency room visits
Atypical LAT Oral AP p value1
(N = 1032) (N = 2796)
Rehospitalizations
All-cause rehospitalizations
Number of rehospitalizations, mean ± SD 1.25 ± 2.09 1.61 ± 2.82 <.0001
Mean number of days in hospital, mean ± SD 13.46 ± 27.48 15.69 ± 30.49 .0081
Time to first rehospitalization, months, mean ± SD 7.47 ± 9.30 7.04 ± 8.86 .2362
Frequency of rehospitalizations, mean ± SD
Within the same month 0.07 ± 0.27 0.09 ± 0.31 .0688
By 1 month 0.15 ± 0.41 0.20 ± 0.49 .0286
By 3 months 0.30 ± 0.62 0.38 ± 0.76 .0288
By 6 months 0.48 ± 0.84 0.58 ± 1.05 .0029
Mental disorder–related rehospitalizations2
Number of rehospitalizations, mean ± SD 1.24 ± 2.08 1.59 ± 2.79 <.0001
Mean number of days in hospital, mean ± SD 13.44 ± 27.46 15.62 ± 30.41 .0093
Time to first rehospitalization, months, mean ± SD 7.46 ± 9.31 7.02 ± 8.84 .2451
Frequency of rehospitalizations, mean ± SD
Within the same month 0.07 ± 0.27 0.09 ± 0.31 .0786
By 1 month 0.15 ± 0.41 0.20 ± 0.49 .0360
By 3 months 0.30 ± 0.62 0.37 ± 0.76 .0333
By 6 months 0.48 ± 0.84 0.58 ± 1.05 .0032
Schizophrenia–related rehospitalizations3
Number of rehospitalizations, mean ± SD 1.15 ± 2.00 1.41 ± 2.54 .0005
Mean number of days in hospital, mean ± SD 12.79 ± 27.07 14.28 ± 29.14 .0893
Time to first rehospitalization, months, mean ± SD 7.39 ± 9.32 7.16 ± 8.99 .4063
Frequency of rehospitalizations, mean ± SD
Within the same month 0.06 ± 0.25 0.08 ± 0.29 .0854
By 1 month 0.14 ± 0.39 0.18 ± 0.46 .1834
By 3 months 0.28 ± 0.60 0.34 ± 0.72 .2080
By 6 months 0.45 ± 0.81 0.52 ± 0.97 .0947
ER Visits
All-cause ER visits
Number of ER visits, mean ± SD 2.33 ± 5.58 2.67 ± 6.38 .0158
Time to first ER visit, months, mean ± SD 6.91 ± 8.82 6.79 ± 8.84 .6060
Frequency of ER visits, mean ± SD
Within the same month 0.08 ± 0.31 0.09 ± 0.34 .4026
By 1 month 0.21 ± 0.60 0.25 ± 0.66 .0482
By 3 months 0.44 ± 1.18 0.50 ± 1.15 .1375
By 6 months 0.75 ± 1.84 0.78 ± 1.61 .3822
Mental disorder–related ER visits2
Number of ER visits, mean ± SD 1.95 ± 4.73 2.08 ± 4.33 .0881
Time to first ER visit, months, mean ± SD 7.41 ± 9.27 7.34 ± 9.41 .6870
Frequency of ER visits, mean ± SD
Within the same month 0.07 ± 0.28 0.08 ± 0.30 .5467
By 1 month 0.18 ± 0.54 0.21 ± 0.55 .2015
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Table 2 Frequency of rehospitalizations and emergency room visits (Continued)
By 3 months 0.38 ± 1.03 0.41 ± 0.94 .4573
By 6 months 0.64 ± 1.46 0.64 ± 1.29 .6932
Schizophrenia–related ER visits3
Number of ER visits, mean ± SD 1.50 ± 3.36 1.54 ± 3.22 .2637
Time to first ER visit, months, mean ± SD 7.77 ± 9.57 7.73 ± 9.56 .7920
Frequency of ER visits, mean ± SD
Within the same month 0.06 ± 0.26 0.06 ± 0.27 .5023
By 1 month 0.15 ± 0.47 0.16 ± 0.45 .5133
By 3 months 0.31 ± 0.90 0.32 ± 0.77 .8963
By 6 months 0.50 ± 1.21 0.50 ± 1.04 .8894
AP, antipsychotics; ER, emergency room; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; LAT, long-acting therapy; SD,
standard deviation.
Notes:
1. Calculated using two-sided paired t tests.
2. At least one diagnosis of mental disorders (ICD-9-CM codes: 290-319) during rehospitalization or ER visit.
3. At least one diagnosis of schizophrenia (ICD-9-CM codes: 295) during rehospitalization or ER visit.
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hospitalizations occurring at the same hospital as no in-
formation on services received outside the hospital or
on pharmacy utilization was available, potentially limit-
ing the ability to fully adjust for differences in baseline
severity of the disease. Additionally, rehospitalizations




























Figure 2 Risk of rehospitalizations and ER visits using Cox proportion
atypical LATs relative to oral APs. AP, antipsychotic; ER, emergency room
disorders (ICD-9 codes: 290-319) during rehospitalization or ER visit. 2. At le
rehospitalization or ER visit. 3. The vertical bars represent the 95% CIs. A HR
with lower rehospitalization and ER visit rates than patients treated with or
one event.the same hospital. Therefore, the rates of hospitalization
may be underestimated; however, it can be assumed that
the rates were underreported equivalently between co-
horts. (d) The lack of clinical data (e.g., PANSS score)
prevented us from assessing patients’ disease severity
and/or the occurrence of a clinically validated relapse
event. Although all these limitations exist, they shouldEmergency-room visits







al hazard models with recurrent events (Andersen-Gill method):
; LAT, long-acting therapy. Notes: 1. At least one diagnosis of mental
ast one diagnosis of schizophrenia (ICD-9 codes: 295) during
<1 indicates that patients receiving atypical LATs were associated
al APs. 4. ER visits resulting in rehospitalizations were counted as
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because neither impacts the relative differences found
between cohorts.
Conclusions
This large hospital database analysis demonstrated that
relapsed patients with schizophrenia treated with atyp-
ical LATs were associated with a 19% lower likelihood of
rehospitalizations compared with patients receiving oral
APs. Atypical LATs were also associated with signifi-
cantly lower ER visit rates and mental disorder-related
and schizophrenia-related rehospitalization rates com-
pared with oral APs. These findings suggest that the effi-
cacy and patient tolerability benefits associated with
improved patient adherence to the injectable form of the
second-generation antipsychotics reduce the demand for
hospitalizations and ER visits among relapsed patients
with schizophrenia. In addition to the clinical benefits,
atypical LATs offer promise for cost savings because of
reduced inpatient hospital utilization.
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